Human albumin solution for resuscitation and volume expansion in critically ill patients

Abstract

There is no evidence that giving human albumin to replace lost blood in critically ill or injured people improves survival when compared to giving saline. Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein), is used to help restore blood volume and hopefully reduce the risk of dying. Blood products (including human albumin), non-blood products or combinations can be used. The review of trials found no evidence that albumin reduces the risk of dying. Albumin is very expensive in which case it may be better to use cheaper alternatives such as saline for fluid resuscitation.

Human serum albumin: From bench to bedside

“…HSA infusions have been used for more than 60 years in the management of a diverse range of medical and surgical problems, including hypovolemia, shock, burns, surgical blood loss, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory distress syndrome, hemodialysis, acute liver failure, chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia (Tullis, 1977a,b;Alexander et al, 1982;Erstad et al, 1991;Hastings and Wolf, 1992;Haynes et al, 2003;Alderson et al, 2004;Liberati et al, 2006). Moreover, HSA infusions have multiple effects, such as volume expansion, increase of the colloid osmotic pressure, and hemodilution.…”

“…HSA is a valuable biomarker of many diseases, including cancer, rheumatoid arthritis, ischemia, post-menopausal obesity, severe acute graft-versus-host disease, and diseases that need monitoring of the glycemic control (Gupta and Lis, 2010;Koga and Kasayama, 2010;Sbarouni et al, 2011). Moreover, HSA is widely used clinically to treat several diseases, including hypovolemia, shock, burns, surgical blood loss, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory distress syndrome, hemodialysis, acute liver failure, chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia (Tullis, 1977a,b;Alexander et al, 1982;Erstad et al, 1991;Hastings and Wolf, 1992;Haynes et al, 2003;Alderson et al, 2004;Liberati et al, 2006). Recently, biotechnological applications of HSA, including implantable biomaterials, surgical adhesives and sealants, biochromatography, ligand trapping, and fusion proteins, have been reported (Bertucci et al, 2010;Furukawa et al, 2011;Komatsu et al, 2011a).…”

Fluid Resuscitation Therapy for Hemorrhagic Shock

“…Additional research is needed to determine optimal fluid resuscitation for hemorrhagic shock. [66][67][68] Therapeutic drug: Dopamine A side effect of using resuscitating fluids such as LR and NS in a patient with hemorrhagic shock is hypoperfusion. Dopamine, an inotropic drug, may be used to increase cardiac output and blood pressure in such patients.…”

Weakening Impact of Excessive Human Serum Albumin (eHSA) on Cisplatin and Etoposide Anticancer Effect in C57BL/6 Mice with Tumor and in Human NSCLC A549 Cells

“…Human serum albumin (HSA) has been used in clinical practice for more than 60 years, which is mainly used for resuscitation and volume expansion in critically ill patients (Liberati et al, 2006). It is the most abundant protein in plasma and one of the major binders/carriers of drugs that plays an important role in pharmacokinetic fate (absorption, distribution, metabolism, and excretion) and pharmacodynamics (Kratz and Beyer, 1998; Leonis et al, 2015; Alam et al, 2016; Ma et al, 2016; Zaloga et al, 2016).…”